On March 9, 2023 OPKO Health, Inc. (NASDAQ: OPK) reported that it will hold an R&D Day event on March 20, 2023 beginning at 4:00 p.m. Eastern time (Press release, Opko Health, MAR 9, 2023, View Source [SID1234628422]). The two-hour virtual event will provide an opportunity to hear from OPKO executives about the ModeX Therapeutics multispecific technology platforms and applications in oncology and infectious diseases. Management will also review the MDX-2201 technology underlying the recently announced license and collaboration agreement with Merck for a vaccine against Epstein-Barr virus. Presenters will include:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Phillip Frost, M.D., Chief Executive Officer and Chairman
Elias Zerhouni, M.D., President and Vice Chairman
Gary Nabel, M.D., Ph.D., Chief Innovation Officer
Ronnie Wei, Ph.D., Head of Biologics Discovery and Development, ModeX Therapeutics
John Mascola, M.D., Chief Scientific Officer, ModeX Therapeutics
Vijay Chhajlani, Ph.D., Chief Technology Officer, ModeX Therapeutics
There is no need to pre-register for the event. A live and archived webcast will be available on OPKO’s Investor Relations website. Following management’s presentations, a Q&A session will be available via the chat function of the webcast.